Co-amoxiclav (Co-amx), erythromycin (Ery), and combined treatments v placebo (Pl) for the composite outcome measure of death, chronic lung disease, or major cerebral abnormality in neonates of women who were in preterm labour*

ComparisonEvent ratesRRR (95% CI)NNT
Co-amx v Pl4.95% v 5.01%1.2% (−34.3 to 27.3)Not significant
*Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article.
Ery v Pl5.63% v 5.01%12.2% (−16.4 to 50.6)Not significant
Combined v Pl5.87% v 5.01%17.0% (−12.7 to 56.9)Not significant